Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases

Neurochemical Research

Volumn 21, Issue 11, 1996, Pages 1469-1488

  Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

addictive disease; Opioid receptors; stress responsivity

Indexed keywords

BUPRENORPHINE; COCAINE; DIAMORPHINE; LEVACETYLMETHADOL; METHADONE; METYRAPONE; NALOXONE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG TOLERANCE; HEROIN DEPENDENCE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; METHADONE TREATMENT; NONHUMAN; OPIATE ADDICTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REINFORCEMENT; WITHDRAWAL SYNDROME;

ANIMALIA; MAMMALIA;

EID: 0029856816     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02532387     Document Type: Article

References (139)

1. Simon, E. J. 1963. Inhibition of RNA synthesis of E. Coli by the narcotic drug levorphanol. Nature. 198:794.
2. Simon, E. J. 1964. Inhibition of bacterial growth by drugs of the morphine series. Science. 144:543.
3. Simon, E. J. and Van Praag, D. 1964. The inhibition of RNA synthesis in E. Coli by levorphanol. Proc. Natl. Acad. Sci. USA. 51:877.
4. Simon, E. J. and Van Praag, D. 1964. Selective inhibition of ribosomal RNA synthesis in E. Coli by levorphanol. Proc. Natl. Acad. Sci. USA. 51:1151.
5. Dole, V. P., Nyswander, M. E. and Kreek, M. J.: Narcotic blockade. Arch. Intern. Med., 118:304-309, 1966.
6. Kreek, M. J. 1992. Epilogue: Medical maintenance treatment for heroin addiction, from a retrospective and prospective viewpoint. Pages 255-272, in State Methadone Maintenance Treatment Guidelines. Office for Treatment Improvement, Division for State Assistance.
7. Kreek, M. J. 1992. The addict as a patient. Pages 997-1009, in Lowinson, J. H., Ruiz, P., Millman, R. B., and Langrod, J. G., (eds.), Substance Abuse: A Comprehensive Textbook. Williams & Wilkins, Baltimore, Maryland.
8. Nyswander, M. 1956. The drug addict as a patient. Grune & Stratton, New York.
9. Dole, V. P., Nyswander, M. E. and Kreek, M. J.: Narcotic blockade: a medical technique for stopping heroin use by addicts. Trans. Assoc. Am. Phys. 79:122-136, 1966.
10. Kreek, M. J. 1991. Using methadone effectively: Achieving goals by application of laboratory, clinical, and evaluation research and by development of innovative programs. Pages 245-266, in Pickens, R., Leukefeld, C., and Schuster, C. R. (eds.) Improving Drug Abuse Treatment, NIDA Research Monograph Series 106, Rockville, MD.
11. Kreek, M. J. 1992. Rationale for maintenance pharmacotherapy of opiate dependence. Pages 205-230, in O'Brien, C. P. and Jaffe, J. H. (eds.), Addictive States, Raven Press, Ltd. New York.
12. Kreek, M. J. 1996. Long-term pharmacotherapy for opiate (primarily heroin) addiction: Opiate Agonists. Pages 487-541, in Schuster, C. R. and Kuhar, M. J. (eds.), Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach, Springer-Verlag, Berlin.
13. Kreek, M. J. 1996. Opiates, opioids and addiction. Mol. Psych., in press.
14. Kreek, M. J. 1996. Cocaine, dopamine and the endogenous opioid system. Journal of Addictive Diseases, (in press).
15. McLellan, A. T., Amdt, I. O., Metzger, D. S., Woody, G. E., and O'Brien, C. P. 1993. The effects of psychosocial services in substance abuse treatment. JAMA 269(15):1953-1959.
16. Ball, J. C. and Ross, A. 1991. The effectiveness of methadone maintenance treatment: Patients, programs, services, and outcome. Springer-Verlag, New York.
17. Inturrisi, C. E. and Verebely, K. 1972. The levels of methadone in the plasma in methadone maintenance. Clin. Pharm. and Ther., 18:633-637.
18. Inturrisi, C. E. and Verebely, K. 1972. Disposition of methadone in man after a single oral dose. Clin. Pharmacol. Ther., 13:923-930.
19. Dole, V. P. and Kreek, M. J. 1973. Methadone plasma level: Sustained by a reservoir of drug in tissue. Proc. Natl. Acad. Sci., 70:10.
20. Kreek, M. J. 1973. Plasma and urine levels of methadone. N.Y. State J. Med., 73:2773-2777.
21. Kreek, M. J., Garfield, J. W., Gutjahr, C. L., and Giusti, L. M. 1976. Rifampin-induced methadone withdrawal. New Engl. J. Med., 294:1104-1106.
22. Kreek, M. J., Gutjahr, C. L., Garfield, J. W., Bowen, D. V., and Field, F. H. 1976. Drug interactions with methadone. Ann. N. Y. Acad. Sci., 281:350-370.
23. Hachey, D. L., Kreek, M. J., and Mattson, D. H. 1977. Quantitative analysis of methadone in biological fluids using deuteriumlabeled methadone and GLC-chemical-ionization mass spectrometry. J. Pharm. Sci., 66:1579-1582.
24. Rubenstein, R. B., Kreek, M. J., Mbawa, N., Wolff, W. I., Korn, R., and Gutjahr, C. L. 1978. Human spinal fluid methadone levels. Drug and Alc. Dep., 3:103-106.
25. Kreek, M. J., Hachey, D. L., and Klein, P. D. 1979. Stereoselective disposition of methadone in man. Life Sci., 24:925-932.
26. Kreek, M. J., Bencsath, F. A., and Field, F. H. 1980. Effects of liver disease on urinary excretion of methadone and metabolites in maintenance patients: Quantitation by direct probe chemical ionization mass spectrometry. Biomedical Mass Spectrometry, 7: 385-395.
27. Novick, D. M., Kreek, M. J., Fanizza, A. M., Yancovitz, S. R., Gelb, A. M., and Stenger, R. J. 1981. Methadone disposition in patients with chronic liver disease. Clin. Pharmacol. Ther., 30: 353-362.
28. 8 methadone. J. Pharm. Sci. 71:39-43.
29. Kreek, M. J., Bencsath, F. A., Fanizza, A., and Field, F. H. 1983. Effects of liver disease on fecal excretion of methadone and its unconjugated metabolites in maintenance patients: Quantitation by direct probe chemical ionization mass spectrometry. Biomed. Mass. Spectrm. 10:544-549.
30. Ingoglia, N. A., and Dole, V. P. 1970. Localization of d- and l-methadone after intra ventricular injection into rat brain. J. Pet. and Ther. 175:84-87.
31. Dole, V. P. 1970. Biochemistry of Addiction. Ann. Rev. of Biochem. 39:821-840.
32. Harte, E. H., Gutjahr, C. L., and Kreek, M. J. 1976. Long-term persistence of dl-methadone in tissues. Clin. Res. 24:623A.
33. Goldstein, A., Lowney, L. T., and Pal, B. K. 1971. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc. Nat. Acad. Sci. USA. 68:1742-1747.
34. Pert, C. B., and Snyder, S. H. 1973. Opiate receptor: demonstration in nervous tissue. Science 179:1011-1014.
35. 3H]Etorphine to rat-brain homogenate. Proceedings of the National Academy of Sciences. 70:1947-1949.
36. Terenius, L. 1973. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacologica ET Toxicologica. 32:317-320.
37. Dole, V. P., and Nyswander, M. E. 1965. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 193:646-650.
38. Kreek, M. J. 1972. Medical safety, side effects and toxicity of methadone. Proceedings of the Fourth National Conference on Methadone Treatment, NAPAN-NIMH, 171-174.
39. Kreek, M. J., Dodes, L., Kane, S., Knobler, J. and Martin, R. 1972. Long-term methadone maintenance therapy: Effects on liver function. Ann. Intern. Med., 77:598-602.
40. Kreek, M. J. 1973. Medical safety and side effects of methadone in tolerant individuals. J. Amer. Med. Assn., 223:665-668.
41. Kreek, M. J. 1973. Physiological implications of methadone treatment. in Methadone Treatment Manual, U.S. Dept. of Justice (USGPO) | 2700-00227, Washington, D.C. 85-91.
42. Cushman, P., and Kreek, M. J. 1974. Methadone-maintained patients. Effects of methadone on plasma testosterone, FSH, LH and prolactin. N.Y. State J. Med. 74:1970-1973.
43. Kreek, M. J. 1978. Medical complications in methadone patients. Ann. N.Y. Acad. Sci., 311:110-134.
44. Cushman, P., and Kreek, M. J. 1974. Some endocrinologie observations in narcotic addicts. Pages 161-173, in Zimmerman, E. and George, R. (eds.) Narcotic and the Hypothalamus, Raven Press, New York, NY.
45. Novick, D. M., Ochshom, M., Ghali, V., Croxson, T. S., Mercer, W. D., Chiorazzi, N., and Kreek, M. J. 1989. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharm. Exper. Ther. 250:606-610.
46. Culpepper-Morgan, J. A., Inturrisi, C. E., Portenoy, R. K., Foley, K., Houde, R. W., Marsh, F., and Kreek, M. J. 1992. Treatment of opioid induced constipation with oral naloxone: A pilot study. Clin. Pharm. Ther. 23:90-95.
47. Novick, D. M., Richman, B. L., Friedman, J. M., Friedman, J. E., Fried, C., Wilson, J. P., Townley, A., and Kreek, M. J. 1993. The medical status of methadone maintained patients in treatment for 11-18 years. Drug and Alc. Dep. 33:235-245.
48. Kreek, M. J., Schaefer, R. A., Hahn, E. F. and Fishman, J. 1983. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet, Feb. 5, 261-262.
49. Kreek, M. J., Fishman, J., Hahn, E. F., and Schaefer, R. A. 1983. Naloxone in chronic constipation (Letter to the editor). Lancet, April 2, 758.
50. Culpepper-Morgan, J., Kreek, M. J., Holt, P. R., La Roche, D., Zhang, J., and O'Bryan, L. 1988. Orally administered kappa as well as mu opiate delay gastrointestinal transit time in the guinea pig. Life Sciences, 42:2073-2077.
51. Culpepper-Morgan, J. A., Holt, P. R., LaRoche, D., and Kreek , M. J. 1995. Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig. Life Sciences. 56:1187-1192.
52. Kreek, M. J. and Culpepper-Morgan, J. A. 1994. Constipation syndromes. Pages 179-208, in Lewis, J. H. (ed.) A Pharmacologic Approach to Gastrointestinal Disorders.
53. Zhang, J. S., Plevy, S., Albeck, H., Culpepper-Morgan, J., Friedman, J. and Kreek, M. J.: Effects of age on distribution of preproenkephalin-like mRNA in the gastrointestinal tract of the guinea pig. Advances in the Biosciences: Proceedings of 1988 INRC meeting, 75:349-350, 1989.
54. Zhang, J., Albeck, H., Culpepper-Morgan, J., Friedman, J., and Kreek, M. J. 1988. Distribution of preproenkephalin mRNA in the gastrointestinal tract of the guinea pig. Clinical Research, 36: 402A.
55. Yuferov, V. P., LaForge, K. S., Spangler, R., Maggos, C. E., and Kreek, M. J. 1996. Guinea Pig Preprodynorphin mRNA: Primary structure and regional quantitation in the brain. DNA and Cell Biology, (in press).
56. Yuferov, V., Culpepper-Morgan, J. A., Claye, L. H., LaForge, K. S., and Kreek, M. J. 1995. Quantification of preprodynorphin (DYN) mRNA in guinea pig gut using a highly sensitive solution hybridization assay. Abstracts of the AGA Meeting, Digestive Disease Week.
57. Eisenman, A. J., Fraser, H. F., Sloan, J., Isbell, and H. 1958. Urinary 17-ketosteroid excretion during a cycle of addiction to morphine. JPET 124:305-311.
58. Stimmel, B., and Kreek, M. J. 1975. Pharmacologic actions of heroin, in: B. Stimmel, (ed.) Heroin dependency: Medical, economic and social aspects, New York, NY: Stratton Intercontinental Medical Book Corp., 71-87.
59. Kreek, M. J. 1975. Pharmacologic modalities of therapy: Methadone maintenance and the use of narcotic antagonists, in B. Stimmel, (ed.), Heroin dependency: Medical, economic and social aspects, New York, NY: Stratton Intercontinental Medical Book Corp., 232-290.
60. Kreek, M. J., Wardlaw, S. L., Friedman, J., Schneider, B., and Frantz, A. G. 1981. Effects of chronic exogenous opioid administration on levels of one endogenous opioid (beta-endorphin) in man. Pages 364-366, in Simon, E. and Takagi, H. (eds.) Advances in Endogenous and Exogenous Opioids,: Kodansha Ltd. Publishers, Tokyo, Japan.
61. Kreek, M. J., and Hartman, N. 1982. Chronic use of opioids and antipsychotic drugs: Side effects, effects on endogenous opioids and toxicity. Ann. N.Y. Acad. Sci., 398:151-172.
62. Kreek, M. J., Wardlaw, S. L., Hartman, N. Raghunath, J., Friedman, J., Schneider, B., and Frantz, A. G. 1983. Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sciences, Sup. I. 33:409-411.
63. Kreek, M. J., Raghunath, J., Plevy, S., Hamer, D., Schneider, B., and Hartman, N. 1984. ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides. 5:277-278.
64. Kennedy, J. A., Hartman, N., Sbriglio, R., Khuri, E., and Kreek, M. J. 1990. Metyrapone-induced withdrawal symptoms. Brit. J. Addict. 85:1133-1140.
65. Piazza, P. V., Maccari, S., Deminiere, J.-M., Le Moal, M., Mormede, M., and Simon, H. 1991. Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc. Natl. Acad. Sci. USA. 33:2088-2092.
66. Piazza, P. V., Deroche, V., Deminiere, J.-M., Maccari, S., Le Moal, M., and Simon, H. 1993. Corticosterone in the range of stress-induced levels possesses reinforcing properties: Implication for sensation-seeking behaviors. Proc. Natl. Acad. Sci. USA. 90:11738-11742.
67. Piazza, P. V., Deminiere, J-M., Le Moal, M., and Simon, H. 1994. Factors that predict individual vulnerability to amphetamine self-administration. Science. 245:1511-1514.
68. Piazza, P. V., Marinelli, M., Jodogone, C., Deroche, V., Rouge-Pont, F., Maccari, S., Le Moal, M., and Simon, H. 1994. Inhibition of Corticosterone synthesis by metyrapone decreases cocaine-induced locomotion and relapse of cocaine self-administration. Brain Res. 658:259-264.
69. Kreek, M. J. 1987. Multiple drug abuse patterns and medical consequences. Pages 1597-1604, in Meltzer, H. Y., (ed.) Psychopharmacology: The Third Generation of Progress, Raven Press, New York.
70. Kreek, M. J. 1992. Rationale for maintenance pharmacotherapy of opiate dependence. Pages 205-230, in O'Brien, C. P. and Jaffe, J. H. (eds.), Addictive States. Raven Press, Ltd., New York.
71. Kreek, M. J., Bencsath, F. A., and Field, F. H. 1980. Effects of liver disease on urinary excretion of methadone and metabolites in maintenance patients: Quantitation by direct probe chemical ionization mass spectrometry. Biomedical Mass Spectrometry. 7: 385-395.
72. Kreek, M. J. 1988. Cocaine effects on neuroendocrine function: relationships to opiate effects and implications for immunological function. Abstracts of the American College of Neuropsychopharmacology.
73. Kreek, M. J., Raghunath, J., Spagnoli, D., Mueller, D., Stubbs, V., and Paris, P. 1986. Possible age-related changes in levels of beta-endorphin in humans. Alcohol Drug Res. 6:117.
74. Kreek, M. J., Marsh, F., Albeck, H., Kutscher, J., Schmugler, J., Connor, B., and Schaefer, R. A. 1986. Effects of opioid antagonist naloxone on fecal evacuation in patients with idiopathic chronic constipation, irritable bowel syndrome, and narcotic-induced constipation. Alcohol Drug Res. 6:168.
75. Kreek, M. J., Paris, P., Beber, C., Bartol, M. A., Newton, B., Mueller, D., Ferdinands, L., and Spagnoli, D. 1986. Improvement of fecal evacuation in geriatric patients by oral administration of the specific opioid antagonist naloxone. Abstracts of the Clinical Pharmacological and Therapeutic Meeting, Stockholm, Sweden.
76. Culpepper-Morgan, J. A., Holt, P. R., and Kreek, M. J. 1988. Colonie opiate receptors change with age: Preliminary data. Page 267, in Harris, L. S. (ed.) Problems of Drug Dependence, 1987; Proceedings of the 49th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Supt. of Docs., U.S. Govt. Print. Off, DHHS Pub.s No. (ADM)88-1564, National Institute of Drug Abuse Research Monograph Series, Washington, D.C.
77. Hahn, E. F., Lahita, R., Kreek, M. J., Duma, C., and Inturrisi, C. E. 1983. Naloxone radioimmunoassay: An improved antiserum. J. Pharm. Pharmacol. 35:833-836.
78. Albeck, H., Woodfield, S., and Kreek, M. J. 1989. Quantitative and pharmacokinetic analysis of naloxone in plasma using high performance liquid chromatography with electrochemical detection and solid phase extraction. J. Chromatog. 488:435-445.
79. Kreek, M. J., Schneider, B. S., Raghunath, J., and Plevy, S. 1984. Prolonged (24 hour) infusion of the opioid antagonist naloxone does not significantly alter plasma levels of Cortisol and ACTH in humans. Abstracts of the Seventh International Congress of Endocrinology, Excerpta Medica, International Congress Series 652, Amsterdam Oxford-Princeton: 845.
80. Volavka, J., Bauman, J., Pevnick, J., Reker, D., James, B., and Cho, D. 1980. Short-term hormonal effects of naloxone in man. Psychoneuroend. 5:225-234.
81. Kreek, M. J., Ochshom, M., Ferdinands, L., O'Bryan, L., Carty, A. 1987. Hypothalamic-pituitary-adrenal axis (HPA) effects in humans of a new opioid antagonist nalmefene with mu and kappa receptor subtype activity. Abstracts of the 1987 INRC Conference. Adelaide, Australia.
82. Schluger, J., Porter, M., Maniar, N., Gunduz, M., Ho, A., and Kreek, M. J. 1996. Differential effects of two opioid antagonists on hypothalamic pituitary adrenal (HPA) axis function in normal controls, in Harris, L. (ed.) Abstracts for the College on Problems of Drug Dependence, 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, in press.
83. Chou, J. Z., Albeck, H., and Kreek, M. J. 1993. Determination of nalmefene in plasma by high performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies. J. Chromatog. 613:359-364.
84. Rosen, M. I., McMahpn, T. J., Margolin, A., Gill, T. S., Woods, S. W., Pearsall, H. R., Kreek, M. J., and Kosten, T. R. 1995. Reliability of sequential naloxone challenge tests. Amer. J. Drug. Alc. Abuse. 4:453-467.
85. Rosen, M. I., McMahon, T. J., Hameedi, F. A., Pearsall, H. R., Woods, S. W., Kreek, M. J., and Kosten, T. R. 1996. Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. J. Pharmacol. and Exp. Therapeutics. 276:1128-1135.
86. Kosten, T. R., Kreek, M. J., Raghunath, J. and Kleber, H. D. 1986. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biological Psychiatry. 21:217-220.
87. Kosten, T. R., Kreek, M. J., Raghunath, J. and Kleber, H. D. 1986. A preliminary study of beta-endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sciences, 39:55-59.
88. Kosten, T.R., Morgan, C. and Kreek, M. J. 1992. Beta-endorphin levels during heroin, methadone, buprenorphine and naloxone challenges: Preliminary findings. Biolog. Psych. 32:523-528.
89. Young, E. A. and Akil, H. 1985. Corticotropin-releasing factor stimulation of adrenocorticotropin and beta-endorphin release: Effects of acute and chronic stress. Endocrinology. 117:23-30.
90. Culpepper-Morgan, J. M., Twist, D. J., Petrillo, C. R., Soda, K. M. and Kreek, M. J. 1992. Beta-endorphin and cortisol abnormalities in spinal cord injured individuals. Metabolism. 41:578-581.
91. Twist, D. J., Culpepper-Morgan, J. A., Ragnarsson, K. T., Petrillo, C. R. and Kreek, M. J. 1992. Neuroendocrine changes during functional electrical stimulation. Am. J. Phys. Med. & Rehab. 71:156-163.
92. Zhou, Y., Spangler, R., LaForge, K. S., Maggos, C. E., Kreek, M. J. 1996. Modulation of CRF-R1 mRNA in rat anterior pituitary by dexamethasone: correlation with POMC mRNA. Peptides, in press.
93. Zhou, Y.; Spangler, R.; LaForge, K. S.; Maggos, C. E., Ho, A. and Kreek, M. J. 1996. Corticotropin-releasing factor and CRF-R1 mRNAs in rat brain and pituitary during "binge" pattern cocaine administration and chronic withdrawal. JPET, in press.
94. Kreek, M. J. and Culpepper-Morgan, J. 1991. Neurocndocrine (HPA) and gastrointestinal effects of opiate antagonists: Possible therapeutic application. Pages 168-174, in Harris, L. S., (ed.), Problems of Drug Dependence, 1990: Proceedings of the 52nd Annual Scientific Meeting of the Committee on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series. Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM) 91-1753, Washington, D.C.
95. Unterwald, E. M., Rubenfeld, J. M., Imai, Y., Wang, J.-B., Uhl, G. R., and Kreek, M. J. 1995. Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol. Brain Res. 33:351-355.
96. Kreek, M. J. 1979. Methadone disposition during the perinatal period in humans. Pharmac. Biochem. Behav., 11, Suppl.:1-7.
97. Burstein, Y., Grady, R. W., Kreek, M. J., Rausen, A. R. and Peterson, C. M. 1980. Thrombocytosis in the offspring of female mice receiving dl-methadone. Proc. Soc. Exp. Biol. Med. 164: 275-279.
98. Unterwald, E., Rubenfeld, J. M., Kreuter, J., Kreek, M. J. 1996. Mu opioid receptor mRNA levels following chronic administration of opioid ligands. Analgesia, in press.
99. Kling, M., Borg, L., Zametkin, A., Schluger, J., Carson, R., Matochik, J., Maslansky, R., Khuri, E., Wells, A., Lampert, S., Lefter, L., Kreuter, J., Herscovitch, P., Eckelman, W., Rice, K., Ho, A. and Kreek, M. J. 1996. Opioid receptor binding in methadone maintained former heroin addicts by PET imaging using (18F)cyclofoxy. in Harris, L. (ed.) Problems of Drug Dependence, 1996; Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, in press.
100. Maggos, C. E., Spangler, R., Perl, D. P., Morgello, S., Simonin, F., Keiffer, B. L., Yuferov, V. and Kreek, M. J. 1996. Human kappa opioid receptor mRNA levels: Quantitation using solution hybridization followed by TCA precipitation, in Harris, L. (ed.) Problems of Drug Dependence, 1996; Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, in press.
101. Volpicelli, J. R., Alterman, A. I., Hayashida, M. and O'Brien, C. P. 1992. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry, 49:876-880.
102. Volpicelli, J. R., Watson, N. T., King, A. C., Sherman, C. E. and O'Brien, C. P. 1995. Effect of naltrexone on alcohol "high" in alcoholics. Amer. J. of Psych. 152:613-15.
103. O'Malley, S. S., Jaffe, A. J., Change, G., Schottenfeld, R. S., Meyer, R. E., and Rounsaville, B. J. 1992. Naltrexone and coping skills therapy for alcohol dependence. Arch. Gen. Psychiatry. 49: 881-887.
104. Mason, B. J., Ritvo, E. C., Morgan, R. O., Salvato, F. R., Goldberg, G., Welch, B., and Mantero-Atienza, E. 1994. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin. Exp. Res. 18:1162-1167.
105. King, A. C., Volpicelli, J. R., Gunduz, M., O'Brien, C. P., and Kreek, M. J. 1996. Naltrexone biotransformation and subjective response to alcohol in social drinkers. Alcoholism: Clin. Expt. Res. 20:44A.
106. Kreek, M. J. 1981. Metabolic interactions between opiates and alcohol. Ann. N.Y. Acad. Sci. 362:36-49.
107. Ragavan, V. V., Wardlaw, S. L., Kreek, M. J. and Frantz, A. G. 1983. Effect of chronic naltrexone and methadone administration on brain immunoreactive beta-endorphin in the rat. Neuroendocrinology. 37:266-268.
108. Kosten, T. R., Kreek, M. J., Swift, C., Carney, M. K. and Ferdinands, L. 1987. Beta-endorphin levels in CSF during methadone maintenance. Life Sciences. 41:1071-1076.
109. Kreek, M. J. 1987. Tolerance and dependence: Implications for the pharmacological treatment of addiction. Pages 53-61, in Harris, L. S., (ed.), Problems of Drug Dependence, 1986; Proceedings of the 48th Annual Scientific Meeting of The Committee on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM) 87-1508, Washington, D.C.
110. Kreek, M. J. 1988. Opiate-ethanol interactions: Implications for the biological basis and treatment of combined addictive diseases. Pages 428-239, in Harris, L. S., (ed.), Problems of Drug Dependence, 1987; Proceedings of the 49th Annual Scientific Meeting of the Committee on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM)88-1564. Washington, D.C.
111. Branch, A. D., Unterwald, E. M., Lee, S. E. and Kreek, M. J. 1992. Quantitation of preproenkephalin mRNA levels in brain regions from male Fischer rats following chronic cocaine treatment using a recently developed solution hybridization procedure. Mol. Brain. Res. 14:231-238.
112. Unterwald, E. M., Home-King, J. and Kreek, M. J. 1992. Chronic cocaine alters brain mu opioid receptors. Brain Res. 584: 314-318.
113. Spangler, R., Unterwald, E. M., Branch, A., Ho, A., and Kreek, M. J. 1993. Chronic cocaine administration increases prodynorphin mRNA levels in the caudate putamen of rats. Page 142 in Harris, L. S. (ed.), Problems of Drug Dependence, 1992; Proceedings of the 54th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (AD1994. Study of dynorphin A (1-17) in vivo processing in rat brain by microdialysis and matrix-assisted M) 93-3505, Washington, D.C.
114. Maisonneuve, I. M., Albeck, H., and Kreek, M. J. 1993. Effects of a series of acute cocaine injections on the dopaminergic systems in rats: An in vivo microdialysis study. Page 396, in Harris, L. S. (ed.), Problems of Drug Dependence, 1992; Proceedings of the 54th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub.No. (ADM) 93-3505, Washington, D.C.
115. Unterwald, E. M., Cox, B. M., Kreek, M. J., Cote, T. E., and Izenwasser, S. 1993. Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity. Synapse. 15:33-38.
116. Spangler, R., Unterwald, E. M., and Kreek, M. J. 1993. 'Binge' cocaine administration induces a sustained increase of prodynorphine mRNA in rat caudate-putamen. Mol. Brain Res. 19:323-327.
117. Chou, J. Z., Maisonneuve, I. M., Chait, B. T. and Kreek, M. J. 1994. Study of dynorphin A(1-17) in vivo processing in rat brain by microdialysis and matrix-assisted laser desorption mass spectrometry. Page 240, in Harris, L. S. (ed.), Problems of Drug Dependence, 1993; Proceedings of the 55th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM)94-3749, Washington, D.C.
118. Maisonneuve, I. M. and Kreek, M. J. 1994. Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats: An in vivo microdialysis study. J. Pharmacol. and Exp. Therapeutics. 268(2):916-921.
119. Unterwald, E. M., Rubenfeld, J. M., and Kreek, M. J. 1994. Repeated cocaine administration upregulates κ and μ, but not δ, opioid receptors. NeuroReport. 5:1613-1616.
120. Unterwald, E. M., Ho, A., Rubenfeld, J. M., and Kreek, M. J. 1994. Time course of the development of behavioral sensitization and dopamine receptor upregulation during binge cocaine administration. J. Pharmacol. and Exp. Therapeutics 270(3):1387-1397.
121. Maisonneuve, I. M., Ho, A., and Kreek, M. J. 1995. Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: An in vivo microdialysis study. J. Pharmacol. and Exp. Therapeutics 272:652-657.
122. Spangler, R., Ho, A., Zhou, Y., Maggos, C., Yuferov, V., Kreek, M. J. 1996. Regulation of kappa opioid receptor mRNA in the rat brain by "binge" pattern cocaine administration and correlation with preprodynorphin mRNA. Mol. Brain Res. 38:71-76.
123. Spangler, R., Zhou, Y., Maggos, C. E., Zlobin, A., Ho, A., and Kreek, M. J. Dopamine antagonist and q "binge" cocaine effects on rat opioid and dopamine transporter mRNAs. Neuroreport, in press.
124. Zubieta, J-K, in Harris, L. (ed.) Problems of Drug Dependence, 1996; Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, in press.
125. Spangler, R., Zhou, Y., Maggos, C. E., Schlussman, S., Ho, A. and Kreek, M. J. 1996. Pesistent Spreprodynorphin and kappa opioid receptor mRNA responses to cocaine occur acutely, in Harris, L. (ed.) Problems of Drug Dependence, 1996; Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, in press.
126. Hurd, Y. L., Herkenham, M. 1992. Influence of a single injection of cocaine, amphetamine or GBR 12909 on mRNA expression of striatal neuropeptides. Mol. Brain Res. 16:97-104.
127. Hurd, Y. L.; Brown, E. E.; Finlay, J. M.; Fibiger, H. C.; Gerfen, C. R. 1992. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Mol. Brain Res. 13:165-170.
128. Daunais, J. B.; Roberts, D. C. S.; McGinty, J. F. 1993. Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. NeuroReport. 4:543-546.
129. Daunais, J. B.; McGinty, J. F. 1995. Cocaine binges differentially alter striatal preprodynorphin mRNA. Mol. Brain Res. 29:201-210.
130. LaForge, K. S., Unterwald, E. M., and Kreek, M. J. 1995. Structure and expression of the guinea pig preproenkephalin gene: Site-specific cleavage in the 3′ untranslated region yields truncated mRNA transcripts in specific brain regions. Mol. and Cell Biology. 15:2080-2089.
131. Yuferov, V. P., LaForge, K. S., Spangler, R., Maggos, C. E., and Kreek, M. J. 1996. Guinea pig preprodynorphin mRNA: Primary structure and regional quantitation in the brain. DNA and Cell Biology, in press.
132. Yuferov, V., LaForge, K. S., Spangler, R., Ho, A. and Kreek, M. J. 1996. Regulation of guinea pig brain preprodynorphin mRNA expression by binge pattern cocaine administration. in Harris, L. (ed.) Problems of Drug Dependence, 1996; Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, in press.
133. Sivam, S. P. 1989. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. JPET. 250:818-824.
134. Chou, J. Z., Pinto, S., Kreek, M. J., and Chait, B. T. 1993. Study of opioid peptides by laser desorption mass spectrometry. Page 380, in Harris, L. S. (ed.), Problems of Drug Dependence, 1992; Proceedings of the 54th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off, DHHS Pub. No.(ADM) 93-3505, Washington, D.C.
135. - man subjects. Page 108, in Harris, L. S. (ed.), Problems of Drug Dependence, 1993; Proceedings of the 55th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off., NIH Pub. No. 94-3749, Washington, D.C.
136. Chou, J. Z., Chait, B. T., and Kreek, M. J. 1995. Study of dynorphin A peptides in vitro processing in human blood by matrix-assisted laser desorption mass spectrometry. Page 252, in Harris, L. S. (ed.), Problems of Drug Dependence, 1994; Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM)95-3883, Washington, D.C.
137. Butelman, E. R., Yu, J., Chou, J. Z., Chait, B. T., Kreek, M. J. and Woods. J. H. 1996. Dynorphin A (1-13): Biotransformation in human and rhesus monkey blood and antinociception. Page 225, in Harris, L. S. (ed.), Problems of Drug Dependence, 1995; Proceedings of the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM)96-4116, Washington, D.C.
138. Yu, J., Butelman, E. R., Woods, J. H., Chait, B. T., and Kreek, M. J. 1996. Studies of in vitro processing of dynorphin A (1-17) in human blood and in rhesus monkey blood. Page 131, in Harris, L. S. (ed.), Problems of Drug Dependence, 1995; Proceedings of the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM)96-4116, Washington, D.C.
139. Claye, L. H., Maisonneuve, I. M., Yu, J., Ho, A. and Kreek, M. J. 1996. Local perfusion of dynorphin A(1-17) reduces extracellular dopamine levels in the nucleus accumbens. in Harris, L. (ed.) Problems of Drug Dependence, 1996; Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, in press.